 |
|
| Blog results | Results 1 - 10 of about 6,056 for raloxifene 60. (0.23 seconds) |
| Sorted by relevance Sort by date |
| 29 Oct 2009 by Legault, Maki, Resnick, Coker, Hogan, Bevers,... Patients and Methods The National Surgical Adjuvant Breast and Bowel Project's Study of Tamoxifen and Raloxifene (STAR) study was a randomized clinical trial of tamoxifen 20 mg/d or raloxifene 60 mg/d in healthy postmenopausal women at ... Journal of Clinical Oncology Current Issue - http://jco.ascopubs.org/ [ More results from Journal of Clinical Oncology Current Issue ] |
| 20 Nov 2009 by admin In a recent, double-blinded, randomized, parallel trial of 390 healthy postmenopausal women, raloxifene in doses of 60 or 120 mg/d was compared to HRT (conjugated estrogens 0.625 mg and medroxyprogesterone 2.5 mg/d) or placebo to ... No SubHealth - http://www.nosubhealth.com/ |
| 25 Sep 2009 by Dr DK Sarwal Earlier, Innovator Eli Lilly got a favorable decision from Court of Appeal for federal Circuit (CAFC) on Feb 24, 2009 w.r.t Raloxifene Hydrochloride 60 mg Tablets. CAFC has delayed Teva's ANDA approval by 6 months. ... IP Pharma Doc - http://ippharmdoc.blogspot.com/ [ More results from IP Pharma Doc ] |
| 10 Nov 2009 by VeZİRH@N In the MORE (Multiple Outcomes of Raloxifene Evaluation) trial, which randomised 7705 osteoporotic, postmenopausal women to 3 years of raloxifene 60 mg bid, 60 mg od, or placebo, the incidence of invasive breast cancer was 76% lower in ... Untitled - http://www.birdunyabilgi.net/ |
| 13 Nov 2009 by Margaret Polaneczky, MD (aka TBTAM) Or whether 100% of women over 60 take a drug that increases their risk for thromboembolism and uterine cancer so that 20% of them won't get breast cancers that some are suggesting may regress or be so indolent that they will die of ... The Blog that Ate Manhattan - http://theblogthatatemanhattan.blogspot.com/ - References |
| 9 Feb 2009 by Collins, P., Mosca, L., Geiger, MJ, Grady,... The effect of raloxifene on the incidence of coronary events differed significantly by age (interaction P=0.0118). The incidence of coronary events in women <60 years of age was significantly lower in those assigned raloxifene (50 ... Circulation recent issues - http://circ.ahajournals.org/ [ More results from Circulation recent issues ] |
| 11 Sep 2009 by Amit Regulatory clearance has been obtained for Synthon's product in nearly all European countries. Synthon's Raloxifene 60 mg tablets are a fully generic and bioequivalent version of the brand product Evista®. The details can be read here. ... Generic Pharmaceuticals and Patents - http://genericspatent.blogspot.com/ |
| 24 Sep 2009 †Antiresorptives and doses accepted for the purposes of this restriction: alendronate 10 mg daily or 70 mg weekly, risedronate 5 mg daily or 35 mg weekly, raloxifene 60 mg daily (women only), etidronate 200 mg with calcium carbonate ... Everything new at NPS - http://www.nps.org.au/home [ More results from Everything new at NPS ] |
| 18 Nov 2009 by Dr.Shruti Bhat In fact, tamoxifen and raloxifene boosted blood clots by 60 percent to 90 percent. Tamoxifen was also more likely than a placebo to lead to endometrial cancer and more likely to cause cataracts than was raloxifene. ... Pharmacy Education And Research .Com - http://www.pharm-education.com/ |
| 24 Aug 2009 by mars1960 The researchers gave the men either 20 mg tamoxifen, 60 mg toremifene or 60 mg raloxifene daily for three months. The table below shows what happened to the men's LH, FSH and testosterone levels. Raloxifene has little effect on the ... UK-Muscle Body Building Community - Bodybuildin... - http://www.uk-muscle.co.uk/ [ More results from UK-Muscle Body Building Community - Bodybuildin... ] |
Stay up to date on these results:
| Google Home - About Google Blog Search Beta - Information for Blog Authors |
